[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 62, Issue 2, 1997, Pages 133-140

  Booij, J ^a,b,d   Tissingh, G ^d   Boer, G J ^c   Speelman, J D ^b   Stoof, J C ^d   Janssen, A G M ^e   Wolters, E Ch ^d   Van Royen, E A ^b  

^a Graduate School Neuroscience Amsterdam   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Dopamine transporter imaging; Parkinson's disease; SPECT

Indexed keywords

2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; CARRIER PROTEIN; DIAGNOSTIC AGENT; DOPAMINE; DOPAMINE TRANSPORTER; MEMBRANE PROTEIN; NERVE PROTEIN; RADIOACTIVE IODINE; TROPANE DERIVATIVE; IODINE 123; RADIOLIGAND;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE PROCESSING; MALE; METABOLISM; MIDDLE AGED; NEOSTRIATUM; PARKINSON DISEASE; PILOT STUDY; PUTAMEN; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CORPUS STRIATUM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; NEUROPATHOLOGY; OUTPATIENT CARE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CAUDATE NUCLEUS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEOSTRIATUM; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PILOT PROJECTS; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0030614902     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.62.2.133     Document Type: Article

References (40)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20:415-55.
2. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991; 9;43-9.
3. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1976;45;19-34.
4. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990; 47:1290-8.
5. 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. Acta Neurol Scand 1988;77:192-201.
6. Marié R-M, Barré L, Rioux P, Allain P, Lechevalier, Baron J-C. PET imaging of neocortical monoaminergic terminals in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1995;9:55-71.
7. 123I]β-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect 1993; 94:137-46.
8. Innis RB, Seibyl JB, Scanley BE, et al. Single photon computed imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Prac Natl Acad Sci USA 1993;90:11965-9.
9. 123I]β-CIT SPECT. Parkinsonism Related Disorders 1995;1:47-51.
10. 123I}β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98.
11. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-31.
12. 11C]β-CFT in early Parkinson's disease. Synapse 1995;21: 97-103.
13. 123I]β-CIT in vivo binding to dopamine transporters in healthy subjects. J Cereb Blood Flow Metab 1994;14:982-94.
14. 123I]N-fluoroalkyl-2β-carboxy-3β-(4-iodophenyl)nortropane esters in baboons. Nucl Med Biol 1995;22:211-9.
15. Neumeyer JL, Wang S, Gao Y, et al. N-ω-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994;37:1558-61.
16. Neumeyer JL, Tamagnan G, Wang S, et al. N-substituted analogs of 2β-carbomethoxy-3β-(4′-iodophenyl)tropane (β-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem 1996;39:543-8.
17. 11C]β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolic studies, and positron emission tomography examinations. Nucl Med Biol 1995;22:905-13.
18. Abi-Dargham A, Gandehnan MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med 1996;37:1129-33.
19. Kuikka JT, Bergström KA, Ahonen A, et al. Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl) tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995;22:356-60.
20. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
21. Van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36: 1175-81.
22. 3H]GBR-12935 in human putamen. Neurobiol Aging 1989;10:661-4.
23. Fahn S, Elton R, Members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-64.
24. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.
25. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
26. 3H]GBR 12935 binding to dopamine uptake sites in the human brain. J Neurochem 1989;53:1400-4.
27. Matsui T, Hirano A. An atlas of the human brain for computerized tomography. Stutgartt, BRD: Gustav Fisher Verlag; 1978.
28. 123I]IBZM as measured with SPECT in MPTP monkeys. Synapse 1994;17:115-24.
29. 2-dopamine receptor binding examined in vivo by PET. Acta Psychiatr Scand 1990; 82:67-71.
30. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;876:876-80.
31. Goto S, Hirano A, Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol 1989; 26:766-70.
32. Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-96.
33. 123I]β-CIT in human plasma may obstruct quantitation of the dopamine transporter. Synapse 1995;19:297-300.
34. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. TINS 1990;13:290-6.
35. 18F]GBR 13119 binding to the DA uptake site. Eur J Pharmacol 1992;216:109-12.
36. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and supranuclear palsy. Ann Neurol 1990;28:547-55.
37. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993;115:1-17.
38. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
39. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46:231-7.
40. 123I]/β-CIT: pharmacological characterization of brain uptake in non-human primates. Synapse 1993;13:295-309.